CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer
- 6 December 2022
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (6) , 1479-1492
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and limited effective treatment options. Notably, immunotherapy is a potential therapeutic approach for TNBC. This study performed single-cell RNA sequencing on TNBC and found highly expressed CXCL9 in M1 macrophages. An intercellular communication network was found between M1 macrophages and M2 macrophages, and M1 macrophages could differentiate into M2 macrophages over time. Meanwhile, CXCL9 expression started to decrease in association with cell differentiation from M1 macrophages to M2 macrophages. Additionally, the M1 macrophage had strong connections to the M2 macrophage in the MHC-II signaling network. Through GSVA analysis, the MHC-II pathway activity of the M1 macrophages was significantly stronger than that of the M2 macrophages. Furthermore, CXCL9 was enriched in the MHC-II signaling pathway. CXCL9 was significantly enriched in the JAK/STAT signaling pathway. Western blot revealed that CXCL9 overexpression promotes JAK1/STAT2 expression in MDA-MB-231 cells. These findings indicate that CXCL9 is a potential clinical biomarker of prognosis and immunotherapy efficacy for TNBC patients. Also, it stimulates JAK/STAT activity, which in turn modifies the tumor microenvironment.Keywords
Funding Information
- Shandong Provincial Natural Science Foundation (ZR2022QH245, ZR2021MH019)
- Scientific Research Foundation for the Introduced Talents of Jinan Central Hospital (YJRC2021011)
- Internationally Standardized Tumour Immunotherapy and Key Technology Platform Construction for Clinical Trials of Drug-Induced Heart Injury (2020ZX09201025)
This publication has 39 references indexed in Scilit:
- Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomasNature Communications, 2015
- Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of CancerCancer Research, 2015
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Prognostic and predictive markers for the new immunotherapies.2014
- Macrophage Activation and Polarization: Nomenclature and Experimental GuidelinesImmunity, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activationJournal of Leukocyte Biology, 2007
- Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysisJournal of Evaluation in Clinical Practice, 2006
- Interferon‐γ‐induced chromatin remodeling at the CIITA locus is BRG1 dependentThe EMBO Journal, 2002